Pharmacoeconomics: Open Access

Paraskevas Kosmidis

Publications

• Research Article
  Treatment Pathways and Associated Costs of Advanced or Metastatic ALK＋ Non-Small Cell Lung Cancer in Greece
  Author(s): Maria Geitona, Hara Kousoulakou, Ioannis Boukovinas, Vassilios Georgoulias, Paraskevas Kosmidis, Georgios Koumakis, Dimitrios Krikelis, Argyro Markouri, Paris Makrantonakis, Epaminondas Samantas and Konstantinos SyrigosMaria Geitona, Hara Kousoulakou, Ioannis Boukovinas, Vassilios Georgoulias, Paraskevas Kosmidis, Georgios Koumakis, Dimitrios Krikelis, Argyro Markouri, Paris Makrantonakis, Epaminondas Samantas and Konstantinos Syrigos
  
  Objective: To investigate the resource use and costs associated with the management of metastatic anaplastic lymphoma kinase inhibitors (ALK+) NSCLC in Greece. Methods: The resource use was based on the outcomes of a Delphi panel with seven oncologists and unit costs derived from officially published sources. Results: The average per patient cost in the current treatment pathway (chemotherapy, crizotinib, chemotherapy, palliative care) was estimated at €67,391. The average per patient cost in future scenario 1 (crizotinib, ceritinib, chemotherapy, palliative care) was estimated at €104,571 (treatment duration 26 months) while in future scenario 2 (chemotherapy, ceritinib, chemotherapy, palliative care) was estimated at €134,215 (treatment duration 29.3 months). Conclusion: Ceritinib as second line treatment leads to an increase in total costs reflecting the longer survi.. Read More»
  DOI: 10.4172/2472-1042.1000109

  Abstract PDF